MANNKIND CORP Increase (Decrease) in Accounts and Notes Receivable
MANNKIND CORP (MNKD) reported Increase (Decrease) in Accounts and Notes Receivable of -$30.56 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable · last filed 2019-02-26
- MANNKIND CORP increase (decrease) in accounts and notes receivable for the quarter ending 2017-12-31 was $0.00.
- MANNKIND CORP increase (decrease) in accounts and notes receivable for the quarter ending 2017-09-30 was $0.00.
- MANNKIND CORP increase (decrease) in accounts and notes receivable for the quarter ending 2017-06-30 was $0.00.
- MANNKIND CORP increase (decrease) in accounts and notes receivable for the quarter ending 2017-03-31 was -$30.56M.
- MANNKIND CORP increase (decrease) in accounts and notes receivable for fiscal 2017 was -$30.56M, a 200.08% decline from fiscal 2016.
- MANNKIND CORP increase (decrease) in accounts and notes receivable for fiscal 2016 was $30.53M.
| Period end | Increase (Decrease) in Accounts and Notes Receivable 3 month | Increase (Decrease) in Accounts and Notes Receivable 6 month | Increase (Decrease) in Accounts and Notes Receivable 9 month | Increase (Decrease) in Accounts and Notes Receivable 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $0.00 derived: sum of 2 quarters · filed 2019-02-26 | $0.00 derived: sum of 3 quarters · filed 2019-02-26 | -$30.56M 10-K · filed 2019-02-26 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | -$30.56M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$30.56M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | -$30.56M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $30.53M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |